Brief: Zevra Therapeutics Announces Top-Line Data From Phase 2 Clinical Trial Of KP1077

Zevra Therapeutics

26/03/2024 21:23

March 26 (Reuters) - Zevra Therapeutics Inc  ZVRA.O :
    * ZEVRA THERAPEUTICS ANNOUNCES TOP-LINE DATA FROM THE PHASE
2
CLINICAL TRIAL OF KP1077 FOR IDIOPATHIC HYPERSOMNIA
    * ZEVRA THERAPEUTICS INC - KP1077 DEMONSTRATES CLINICALLY
MEANINGFUL BENEFITS FOR KEY IH SYMPTOMS
    * ZEVRA THERAPEUTICS INC - PLANS TO REQUEST AN END-OF-PHASE
2
(EOP2) MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION
    * ZEVRA THERAPEUTICS INC - STUDY ALSO SUCCESSFULLY FULFILLED
OBJECTIVES OF PROVIDING KEY INFORMATION FOR DESIGN OF A
POTENTIALLY PIVOTAL EFFICACY TRIAL
    * ZEVRA THERAPEUTICS INC - RESULTS OF SECONDARY EFFICACY
ENDPOINTS
WERE SUPPORTIVE OF INITIATING A PHASE 3 TRIAL OF KP1077
    * ZEVRA THERAPEUTICS INC - KP1077 WAS SHOWN TO BE
WELL-TOLERATED
AT ALL DOSE LEVELS EVALUATED IN TRIAL

Source text for Eikon:  ID:nGNXnv8r6 
Further company coverage:  ZVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))